These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 15928673)

  • 1. Disrupting tumour blood vessels.
    Tozer GM; Kanthou C; Baguley BC
    Nat Rev Cancer; 2005 Jun; 5(6):423-35. PubMed ID: 15928673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents].
    Cai YC; Zou Y; Xian LJ
    Yao Xue Xue Bao; 2010 Mar; 45(3):283-8. PubMed ID: 21351502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular disrupting agents in clinical development.
    Hinnen P; Eskens FA
    Br J Cancer; 2007 Apr; 96(8):1159-65. PubMed ID: 17375046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current development status of small-molecule vascular disrupting agents.
    Chaplin DJ; Horsman MR; Siemann DW
    Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.
    Kanthou C; Tozer GM
    Int J Exp Pathol; 2009 Jun; 90(3):284-94. PubMed ID: 19563611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The biology of the combretastatins as tumour vascular targeting agents.
    Tozer GM; Kanthou C; Parkins CS; Hill SA
    Int J Exp Pathol; 2002 Feb; 83(1):21-38. PubMed ID: 12059907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth.
    Pérez-Pérez MJ; Priego EM; Bueno O; Martins MS; Canela MD; Liekens S
    J Med Chem; 2016 Oct; 59(19):8685-8711. PubMed ID: 27348355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taking down tumors: vascular disrupting agents entering clinical trials.
    O'Hanlon LH
    J Natl Cancer Inst; 2005 Sep; 97(17):1244-5. PubMed ID: 16145041
    [No Abstract]   [Full Text] [Related]  

  • 9. The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.
    Head M; Jameson MB
    Expert Opin Investig Drugs; 2010 Feb; 19(2):295-304. PubMed ID: 20050824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular disrupting agents: a new class of drug in cancer therapy.
    Gaya AM; Rustin GJ
    Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):277-90. PubMed ID: 15997924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.
    McKeage MJ; Baguley BC
    Cancer; 2010 Apr; 116(8):1859-71. PubMed ID: 20166210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASA404: update on drug development.
    Rehman F; Rustin G
    Expert Opin Investig Drugs; 2008 Oct; 17(10):1547-51. PubMed ID: 18808313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour targeting by microtubule-depolymerizing vascular disrupting agents.
    Kanthou C; Tozer GM
    Expert Opin Ther Targets; 2007 Nov; 11(11):1443-57. PubMed ID: 18028009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule vascular disrupting agents: potential new drugs for cancer treatment.
    Cai SX
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):79-101. PubMed ID: 18221055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular disrupting agent drug classes differ in effects on the cytoskeleton.
    Kim S; Peshkin L; Mitchison TJ
    PLoS One; 2012; 7(7):e40177. PubMed ID: 22848372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AVE8062: a new combretastatin derivative vascular disrupting agent.
    Delmonte A; Sessa C
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1541-8. PubMed ID: 19758109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour vascular disrupting agents: combating treatment resistance.
    Tozer GM; Kanthou C; Lewis G; Prise VE; Vojnovic B; Hill SA
    Br J Radiol; 2008 Oct; 81 Spec No 1():S12-20. PubMed ID: 18819993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).
    Siemann DW; Chaplin DJ; Walicke PA
    Expert Opin Investig Drugs; 2009 Feb; 18(2):189-97. PubMed ID: 19236265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New vascular disrupting agents in upper gastrointestinal malignancies.
    Quatrale AE; Porcelli L; Gnoni A; Numico G; Paradiso A; Azzariti A
    Curr Med Chem; 2014; 21(8):1039-49. PubMed ID: 23992324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours.
    Dalal S; Burchill SA
    Eur J Cancer; 2009 Mar; 45(4):713-22. PubMed ID: 19136249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.